Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 2Recruiting 1Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Head & Neck 1Gynecologic 1Endocrine 1Breast 1

Conditions

Sarcoma 111Osteosarcoma 41Sarcoma, Ewing 30Rhabdomyosarcoma 28Melanoma 28Neuroblastoma 21Glioblastoma 18Bone Neoplasms 18Rhabdoid Tumor 17Lymphoma, Non-Hodgkin 17Gliosarcoma 16Neoplasms 15Neoplasm Metastasis 15Liposarcoma 15Breast Neoplasms 15Wilms Tumor 14Ovarian Neoplasms 14Glioma 14Medulloblastoma 13Leiomyosarcoma 13Gastrointestinal Stromal Tumors 13Carcinoma, Non-Small-Cell Lung 13Stomach Neoplasms 12Hepatoblastoma 12Colorectal Neoplasms 12Sarcoma, Synovial 11Ependymoma 11Chordoma 11Carcinoma, Renal Cell 11Neurofibrosarcoma 10

Interventions

fludarabine 1aldesleukin 1Nivolumab 1Ipilimumab 1Cyclophosphamide 1CTLA-4 Antigen 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × Giant Cell Tumor of Bone × Sarcoma × Clear all
NCT03449108 2026-05-22

LN-145 or LN-145-S1 in Treating Patients With Relapsed or Refractory Ovarian Cancer, Triple Negative Breast Cancer (TNBC), Anaplastic Thyroid Cancer, Osteosarcoma, or Other Bone and Soft Tissue Sarcomas

M.D. Anderson Cancer Center

Phase 2 Active not recruiting
30 enrolled
BreastEndocrineGynecologicHead & NeckSarcoma

Bone Neoplasms, Ovarian Neoplasms, Sarcoma, Osteosarcoma, Giant Cell Tumor of Bone, Histiocytoma, Malignant Fibrous, Triple Negative Breast Neoplasms, Thyroid Carcinoma, Anaplastic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡